Immutep (IMMP) Competitors $1.86 +0.04 (+2.20%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$1.83 -0.03 (-1.61%) As of 03/28/2025 05:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMMP vs. BGM, MLYS, NRIX, VIR, NTLA, COLL, RCUS, RCKT, XNCR, and ZYMEShould you be buying Immutep stock or one of its competitors? The main competitors of Immutep include Qilian International Holding Group (BGM), Mineralys Therapeutics (MLYS), Nurix Therapeutics (NRIX), Vir Biotechnology (VIR), Intellia Therapeutics (NTLA), Collegium Pharmaceutical (COLL), Arcus Biosciences (RCUS), Rocket Pharmaceuticals (RCKT), Xencor (XNCR), and Zymeworks (ZYME). These companies are all part of the "pharmaceutical products" industry. Immutep vs. Qilian International Holding Group Mineralys Therapeutics Nurix Therapeutics Vir Biotechnology Intellia Therapeutics Collegium Pharmaceutical Arcus Biosciences Rocket Pharmaceuticals Xencor Zymeworks Qilian International Holding Group (NASDAQ:BGM) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation, institutional ownership and community ranking. Does the MarketBeat Community prefer BGM or IMMP? Immutep received 312 more outperform votes than Qilian International Holding Group when rated by MarketBeat users. CompanyUnderperformOutperformQilian International Holding GroupN/AN/AImmutepOutperform Votes31272.56% Underperform Votes11827.44% Which has higher earnings and valuation, BGM or IMMP? Qilian International Holding Group has higher revenue and earnings than Immutep. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQilian International Holding Group$25.10M43.97-$1.44MN/AN/AImmutep$5.14M52.67-$28.01MN/AN/A Which has more volatility & risk, BGM or IMMP? Qilian International Holding Group has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500. Comparatively, Immutep has a beta of 2.34, suggesting that its stock price is 134% more volatile than the S&P 500. Does the media favor BGM or IMMP? In the previous week, Immutep had 2 more articles in the media than Qilian International Holding Group. MarketBeat recorded 3 mentions for Immutep and 1 mentions for Qilian International Holding Group. Qilian International Holding Group's average media sentiment score of 1.87 beat Immutep's score of 0.87 indicating that Qilian International Holding Group is being referred to more favorably in the media. Company Overall Sentiment Qilian International Holding Group Very Positive Immutep Positive Do analysts recommend BGM or IMMP? Immutep has a consensus target price of $8.50, suggesting a potential upside of 356.99%. Given Immutep's stronger consensus rating and higher probable upside, analysts clearly believe Immutep is more favorable than Qilian International Holding Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qilian International Holding Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Immutep 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in BGM or IMMP? 2.3% of Immutep shares are held by institutional investors. 58.7% of Qilian International Holding Group shares are held by company insiders. Comparatively, 3.1% of Immutep shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is BGM or IMMP more profitable? Company Net Margins Return on Equity Return on Assets Qilian International Holding GroupN/A N/A N/A Immutep N/A N/A N/A SummaryImmutep beats Qilian International Holding Group on 8 of the 12 factors compared between the two stocks. Remove Ads Get Immutep News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMMP vs. The Competition Export to ExcelMetricImmutepPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$264.92M$6.90B$5.63B$7.83BDividend YieldN/A2.74%4.57%4.01%P/E RatioN/A7.1723.3318.67Price / Sales52.67218.11387.5690.67Price / CashN/A65.6738.1634.64Price / Book1.776.396.894.23Net Income-$28.01M$142.12M$3.20B$247.15M7 Day Performance-1.06%-5.06%-2.98%-2.17%1 Month Performance-3.63%-7.49%1.63%-5.68%1 Year Performance-20.17%-10.91%9.44%-0.74% Immutep Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMPImmutep1.8505 of 5 stars$1.86+2.2%$8.50+357.0%-20.2%$264.92M$5.14M0.002,021BGMQilian International Holding GroupN/A$10.94-0.5%N/AN/A$1.06B$25.10M0.00298Gap UpMLYSMineralys Therapeutics3.0921 of 5 stars$16.17-4.1%$27.00+67.0%+13.6%$1.02BN/A-4.4428High Trading VolumeNRIXNurix Therapeutics2.028 of 5 stars$13.34+2.7%$30.88+131.5%-17.3%$1.01B$54.55M-4.62300VIRVir Biotechnology3.5541 of 5 stars$7.20+3.9%$35.67+395.4%-33.9%$987.43M$63.71M-1.84580NTLAIntellia Therapeutics4.4509 of 5 stars$9.31+3.4%$37.56+303.4%-70.7%$963.74M$57.88M-1.71600Analyst RevisionCOLLCollegium Pharmaceutical4.0564 of 5 stars$30.56+1.7%$43.60+42.7%-23.5%$962.21M$631.45M13.17210Analyst RevisionRCUSArcus Biosciences2.2474 of 5 stars$9.15+2.3%$30.25+230.8%-56.8%$961.49M$258M-2.90500Gap DownRCKTRocket Pharmaceuticals4.6308 of 5 stars$8.73+3.6%$43.00+392.6%-71.8%$930.88MN/A-3.17240XNCRXencor3.4318 of 5 stars$12.95-1.9%$34.38+165.4%-49.3%$912.48M$110.49M-4.05280ZYMEZymeworks2.6199 of 5 stars$13.05+2.6%$21.00+60.9%+17.6%$907.98M$76.30M-8.70460Insider TradePositive News Remove Ads Related Companies and Tools Related Companies Qilian International Holding Group Alternatives Mineralys Therapeutics Alternatives Nurix Therapeutics Alternatives Vir Biotechnology Alternatives Intellia Therapeutics Alternatives Collegium Pharmaceutical Alternatives Arcus Biosciences Alternatives Rocket Pharmaceuticals Alternatives Xencor Alternatives Zymeworks Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMMP) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immutep Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Immutep With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
